

David Grainger, University of Utah, USA

David W. Grainger is the *University Distinguished Professor and George S. and Dolores Doré Eccles Presidential Endowed Chair in Pharmaceuticals and Pharmaceutical Chemistry, and Department Chair and Professor of Bioengineering* at the University of Utah, USA. Grainger's research focuses on improving drug delivery methods, implanted medical device and diagnostics performance, and nanomaterials toxicity. Grainger has published nearly 200 research papers and 30 book chapters on biomaterials innovation in medicine and biotechnology, and novel surface and diagnostics chemistry. His research awards include a 2016 *Fulbright Scholar Award* (New Zealand), the 2013 *Excellence in Surface Science Award* (Surfaces in Biomaterials Foundation), the 2007 *Clemson Award for Basic Research* (Society for Biomaterials), and the 2005 American Pharmaceutical Research and Manufacturer's Association's award for "*Excellence in Pharmaceuticals*". Grainger has served as Chair of several prominent USA research review panels and now serves on the NIH NIBIB Council. He serves on the editorial boards for 6 major journals, past handling editor for the journal, *Biomaterials*, for nearly two decades, and a special topics editor for *Advanced Drug Delivery Reviews*. Grainger has also won numerous teaching awards and has provided over 370 invited lectures and outreach workshops globally. He consults widely for the biomedical device and pharmaceutical industry and has been a principal in 6 biotech start-up commercialization efforts. Grainger continues to emphasize translational approaches to clinical biomaterials, implant validation in infection mitigation, and drug delivery systems.